Lumen Bioscience co-founder and CEO Brian Finrow said the company is looking for people newly diagnosed with the infection for its trials.
Lumen Bioscience secures DOD funding for infection treatment
Recent Post
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases